Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib vs bevacizumab first-line maintenance in HRD-negative advanced epithelial ovarian cancer
ChiCTR2400081039Phase 2Not yet recruiting
- Sponsor
- West China Second University Hospital
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of anlotinib and bevacizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by West China Second University Hospital. Primary endpoint: Progression-free survival. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
anlotinibbevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2400081039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081039.